CTMX
CytomX Therapeutics·NASDAQ
--
--(--)
--
--(--)
5.75 / 10
Netural
Analyst consensus is overwhelmingly bullish: 80% Buy and 20% Strong Buy ratings from four active analysts, with a historical weighted rating of 4.17. Fund flow analysis shows a 7.33/10 score, with positive Small and Large inflow trends despite overall negative flow. This combination of strong analyst conviction and robust money inflows supports the technical strength, but investors should remain mindful of the stock's fundamental weaknesses.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
20%
Buy
80%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-02-04
InstitutionBarclays
Times predicted4
Historical Win Rate75.0%
Is money flowing into or out of CTMX?
- CTMX holds a Bearish analyst rating, with 80% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 5.75/10 (Netural).
